Novel Prostate Nanomedicine Delivers High Drug Concentration Directlyand Safely to Tumors in Phase I Trials
Novel Prostate Nanomedicine Delivers High Drug Concentration Directlyand Safely to Tumors in Phase I Trials
Highly-Targeted Nanoparticles Act as “Trojan Horse” to Deliver Powerful Chemotherapy Agent Without Affecting Healthy Cells
Acceleron’s ACE-041 Combined with a VEGF Inhibitor Shows Potent Activity in Preclinical Model of VEGF-Resistant Renal Cell Carcinoma
Acceleron’s ACE-041 Combined with a VEGF Inhibitor Shows Potent Activity in Preclinical Model of VEGF-Resistant Renal Cell Carcinoma
-- Enhanced Anti-Tumor Activity Achieved via Combination of Two Distinct Anti-Angiogenic Drugs presented at the AACR Annual Meeting 2012 --
Bind Biosciences - Fierce's 5 Drug Delivery Companies to Watch
Bind Biosciences - Fierce's 5 Drug Delivery Companies to Watch
Company: Bind Biosciences
Headquarters: Cambridge, MA
Founded: 2006
Employees: 30
Core drug delivery technology: Bind's Accurins technology blends polymers with existing drugs to create an enhanced, controlled-release compound that hits a precise target with its payload. Bind's first drug, Bind-014, is a formulation of docetaxel, the active ingredient in Taxotere, a drug that treats breast, prostate, lung and other cancers.
Tetraphase Presents Data at ECCMID from Growing Portfolio of Next-Generation Antibiotic Candidates
Tetraphase Presents Data at ECCMID from Growing Portfolio of Next-Generation Antibiotic Candidates
ACOS and Avedro Announce Initiation of a Phase 3 Study On Accelerated Corneal Cross-Linking
ACOS and Avedro Announce Initiation of a Phase 3 Study On Accelerated Corneal Cross-Linking
ACOS (The American-European Congress of Ophthalmic Surgery) and Avedro, Inc. jointly announced today the initiation of a Phase 3, multi-center, randomized, controlled evaluation to study accelerated corneal collagen cross-linking in eyes with keratoconus or corneal ectasia after refractive surgery. ACOS is sponsoring the study, which will be conducted in 100 clinical centers across the United States.
Mascoma and Lallemand Ethanol Technology Announce Commercial Agreement with Pacific Ethanol for Drop-In MGT™ Yeast Product and Commercial Roll-Out Progress
Mascoma and Lallemand Ethanol Technology Announce Commercial Agreement with Pacific Ethanol for Drop-In MGT™ Yeast Product and Commercial Roll-Out Progress
Mascoma Corporation, a renewable fuels company, and Lallemand Ethanol Technology, a leading supplier of fermentation ingredients to fuel ethanol producers, announced today that they have entered into a commercial agreement with Pacific Ethanol Columbia, LLC, the owner of the ethanol production facility located in Boardman, Oregon and operated by Pacific Ethanol, Inc., (NASDAQ: PEIX), the leading marketer and producer of low-carbon renewable fuels in the Western United States.
BG Medicine, Inc. Announces Important New Galectin-3 Findings Presented at American College of Cardiology's (ACC) 61st Annual Scientific Session & Expo
BG Medicine, Inc. Announces Important New Galectin-3 Findings Presented at American College of Cardiology's (ACC) 61st Annual Scientific Session & Expo
BG Medicine, Inc. (Nasdaq:BGMD - News), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today the results of several new studies related to the galectin-3 protein. BG Medicine markets a blood test for galectin-3 called the BGM Galectin-3 test for heart failure, which was cleared by the FDA in 2010 and obtained the CE mark for commercialization in the EU.
LS9 Wins Sustainable Biofuels Technology Award Presented by World Biofuels Markets
LS9 Wins Sustainable Biofuels Technology Award Presented by World Biofuels Markets
SOUTH SAN FRANCISCO, Calif., Mar 16, 2012 (GlobeNewswire via COMTEX) -- LS9, Inc., a technology leader in the development of renewable and sustainable products, today announced the Company was chosen by an independent panel of judges as the winner of the Sustainable Biofuels Technology Award presented at the World Biofuels Markets Congress and Exhibition 2012 taking place March 13-15, 2012 at the Beurs-World Trade Center, in the Rotterdam, Netherlands ( www.worldbiofuelsmarkets.com ).<
LS9 Wins Sustainable Biofuels Technology Award Presented by World Biofuels Markets
LS9 Wins Sustainable Biofuels Technology Award Presented by World Biofuels Markets
SOUTH SAN FRANCISCO, Calif., Mar 16, 2012 (GlobeNewswire via COMTEX) -- LS9, Inc., a technology leader in the development of renewable and sustainable products, today announced the Company was chosen by an independent panel of judges as the winner of the Sustainable Biofuels Technology Award presented at the World Biofuels Markets Congress and Exhibition 2012 taking place March 13-15, 2012 at the Beurs-World Trade Center, in the Rotterdam, Netherlands ( www.worldbiofuelsmarkets.com ).<
Tom Bogan Joins Black Duck Software as Chairman of the Board
Tom Bogan Joins Black Duck Software as Chairman of the Board
BURLINGTON, Mass., March 15, 2012 -- Black Duck Software, the leader in open source software knowledge,


